Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 5,232 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Spiramycin; Drug
Lead sponsor: Rhone-Poulenc Rorer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Horsham, Pennsylvania

Conditions: Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 0 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Uveitis
Interventions: Daclizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus Infections
Interventions: MF-59, Placebo, CMV gB vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more

Conditions: TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC), Subarachnoid Hemorrhage, Aneurysmal, Ischemic Stroke, Intracerebral Hemorrhage
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years to 85 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Lexington, Kentucky • Columbus, Ohio

Conditions: Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions: INNA-051, Placebo; Drug · Other
Lead sponsor: ENA Respiratory Pty Ltd; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Bethesda, Maryland • College Park, Maryland + 3 more

Conditions: COVID-19
Interventions: Hydroxychloroquine (HCQ); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more

Conditions: Ureaplasma, Bacterial Infection
Interventions: Azithromycin; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 30 Days
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Detroit, Michigan • Cleveland, Ohio

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more

Conditions: Cryptosporidium Infection, Cryptosporidiosis
Interventions: Cryptosporidium parvum oocysts (ABO809); Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Interventions: D-PLEX, Standard of Care (SoC); Drug
Lead sponsor: PolyPid Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 977 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Sheffield, Alabama • Los Angeles, California • Redding, California + 2 more

Conditions: Otitis Media Acute
Interventions: PhotoniCare OtoSight Middle Ear Scope; Device
Lead sponsor: PhotoniCare, Inc.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Onychomycosis of Toenail
Interventions: P-3058 (terbinafine hydrochloride 10%), Vehicle of P-3058; Drug
Lead sponsor: Polichem S.A.; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: North Hollywood, California • Oceanside, California • San Diego, California + 15 more

Conditions: Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, Ventriculitis
Interventions: IRRAflow with Active Fluid Exchange System, External Ventricular Drain; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV
Interventions: SB-728mR-HSPC Infusion 3 days following busulfan conditioning; Genetic
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 1 more

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
Interventions: PREVENT - BCT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Crohn's Disease
Interventions: Fludarabine, Cyclophosphamide, Mesna, Alemtuzumab, G-CSF, Rifaximin, Tacrolimus; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 49 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Socket, Wound Infection
Interventions: Colgate Total Toothpaste, Colgate Regular Toothpaste; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 35 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cytomegalovirus Infections
Interventions: CMV-Peptide-Specific T cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 6 more

Search by objective public record fields.

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Augmented Renal Clearance in Neurocritical Care

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

COVID-19 PrEP HCW HCQ Study

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Study of Efficacy and Safety of ABO809 in Healthy Participants

D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

Clinical Development of Deep Learning for the OtoSight

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

MVA Post-Event: Administration Timing and Boost Study

PREVENT HPV-Related Cancers - BootCamp Translation

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Autologous Transplant Targeted Against Crohn's

Triclosan Toothpaste and Third Molar Surgery

Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children